Prognostic Significance of Pim1 Expression in Primary Nodal Diffuse Large B-cell Lymphoma
|Keywords||Diffuse large B-cell lymphoma pim1 Prognosis Chemotherapy Survive|
Background and Purpose blocked cell proliferation and apoptosis is critical tumorigenesis of DLBCL tumor cell proliferation and apoptosis, help to reveal the mechanism of the development of DLBCL, understanding of tumor biology for tumor diagnosis , treatment and prognosis provide valuable indicators. Pim1 in most tumor tissue, inhibits apoptosis, and promote the function of tumor cell proliferation. In this study, the people of NHL epidemiological characteristics of selected patients with pathological type of predilection DLBCL, using immunohistochemical techniques to detect the expression of DLBCL Pim1 explore pim1 with primary diffuse large B-cell nodular lymphoid tumors (DLBCL) prognosis. Materials and Methods Nantong, Shanghai Sixth People's Hospital and the University Hospital in January 2002 -2006 in February confirmed the origin of the initial issuance of lymph DLBCL 53 patients were analyzed retrospectively. Application rabbit polyclonal antibody against human pim1, using immunohistochemical SP method, based on the principle of antigen-antibody reaction to detect 53 cases of patients with DLBCL pim1 expression with clinical and pathological data were statistically analyzed. Results 1.Pim1 DLBCL patients in the expression: In the 53 cases of DLBCL patients, 24 (45.2%) cases pim1 high expression, pim1 high expression in age, gender, LDH level, stage, B (or without) symptoms There was no significant difference (P gt; 0.05), in the IPI group, germinal center phenotype, bone marrow involvement (or without), complete remission rate of chemotherapy-related differences (P lt; 0.05). 2. Pim1 expression on chemotherapy in patients with complete remission rate of: All of the 53 patients all received at least 6-8 cycles of CHOP regimen of chemotherapy, Pim1 chemotherapy in patients with high expression of the complete remission rate was 29.2%, pim1 low expression chemotherapy in patients with complete remission rate was 68.9% (p = 0.006). In univariate logistic regression analysis shows pim1 chemotherapy in patients with high expression of complete remission rate of OR = 0.263 (95% CI, 0.084-0.825; P = 0.022). Including pim1 and IPI in multivariate logistic regression analysis, pim1 chemotherapy in patients with high expression of complete remission rate of OR = 0.374 (95% CI, 0.110-1.278; P = 0.117), high-IPI group OR = 0.235 (95% CI , 0.069-0.801; P = 0.021). 3. Pim1 expression on the prognosis of patients affected: All 53 patients were all received at least 6-8 cycles of CHOP chemotherapy program, with an average follow-up time of 32 months (1-86 months), 3-year overall survival rate was 47.2%. Kaplan-Meier analysis showed: Pim1 high expression than in patients with low expression pim1 3-year overall survival in patients with low (P lt; 0.001). Univariate Cox regression analysis showed that, pim1 high expression RR = 3.755 (95% CI ,1.684-8 .375; P lt; 0.001). Including pim1 and IPI in multivariate Cox regression analysis showed that, pim1 high expression RR = 2.756 (95% CI ,1.197-6 .347; P = 0.017); IPI's RR = 2.947 (95% CI ,1.203-7 .219; P = 0.018 ). Conclusion 1.Pim1 expression and gender, age, clinical stage, B symptoms without, LDH level, ≥ 2 knots outside the affected area has nothing to do with the IPI grouping, germinal center phenotype, bone marrow involvement (or without), chemotherapy completely remission rate related. 2.Pim1 high expression rate of complete remission after chemotherapy than patients with low expression pim1 low. 3.Pim1 patients with high expression 3-year overall survival than patients with low expression pim1 low.